[{"from": "human", "value": "Please give me some details about this molecule. [C][C][S][=Branch1][C][=O][=Branch1][C][=O][N][C][C][Branch1][Ring2][C][Ring1][Ring2][Branch1][Ring2][C][C][#N][N][C][=C][Branch1][Branch1][C][=N][Ring1][Branch1][C][=C][C][=C][N][C][Ring1][Branch1][=N][C][=N][Ring1][=Branch2]"}, {"from": "gpt", "value": "The molecule is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.  Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022."}]